AIDS Research and Therapy · 2015 · 21 citations · 35 references
MedicineNeurologyNeuroscienceCognitive NeuroscienceDementiaNeurodegenerationAlzheimer DiseaseCerebrospinal Fluid BiomarkersCognitive ImpairmentDementia BiomarkersNeurodegenerative DiseasesNeurodegenerative DisordersBiomarkersCerebrospinal Fluid Neurodegeneration MarkersCerebrospinal Fluid TauHiv-associated Cognitive ImpairmentHiv-associated DementiaNeurocognitive DeclineNeurocognitive DeficitsNeurocognitive Profile
It is a challenge to differentiate between HIV-associated neurocognitive disorders (HAND) and other types of neurocognitive disease in the ageing HIV-infected population. Here we describe a 63 year old HIV-infected woman who had a history, neuropsychological test result, and PET examination consistent with characteristic Alzheimer's disease (AD). The cerebrospinal fluid (CSF) biomarker profile was analogous to the profile typically found in AD in HIV-negative patients with increased t-tau and p-tau, a decreased level of Aβ42 and normal levels of CSF neurofilament light protein and sAPPα and sAPPβ, distinctly different from findings in HIV-associated dementia (HAD). Assessment of CSF biomarkers may be a valuable tool for clinicians to distinguish between HAD and AD.
35
Guy M. McKhann, David S. Knopman, Howard Chertkow et al. · Alzheimer s & Dementia · 2011 · 18.8K citations · Full text
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy
Robert K. Heaton, David B. Clifford, Donald Franklin et al. · Neurology · 2010 · 2.3K citations · Full text
Medicine, Neurology, Psychiatry +17
tau protein in cerebrospinal fluid
Kaj Blennow, Anders Wallin, Hans Ågren et al. · Molecular and Chemical Neuropathology · 1995 · 799 citations
Medicine, Neurology, Neuroscience +17